Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: knee pain

Centrexion’s Chili-Based Painkiller Offers Relief for 6 Months—Study

Natalie Grover  |  June 14, 2017

(Reuters)—A synthetic version of a medicine traditionally extracted from chili plant relieved knee pain among osteoarthritis patients for up to six months, data showed, bringing Centrexion Therapeutics a step closer to developing a safe and effective analgesic. The drug, designed to be injected at the site of pain, is being developed by the privately-held company…

Filed under:Drug UpdatesOsteoarthritis and Bone Disorders Tagged with:CentrexionChili-Based PainkillerCNTX-4975knee pain

Surgery Won’t Help Degenerative Knee Problems

Marilynn Larkin  |  May 15, 2017

(Reuters Health)—Arthroscopic surgery won’t cure chronic knee pain, locking, clicking, a torn meniscus or other problems related to knee arthritis, according to a panel of international experts. Every year, more than two million people with degenerative knee problems have arthroscopic surgery. But guidelines published May 10 in the British Medical Journal recommend against the procedure…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:arthroscopic meniscal surgeryExercise/physical therapykneeknee arthroscopyknee pain

How to Leverage Physical Therapy & Technology to Help Patients Stay Fit & Decrease Pain

Carina Stanton  |  March 28, 2017

For patients living with rheumatic diseases, the benefits of physical therapy and exercise cannot be overstated. “Working with a physical therapist provides a chance for careful evaluation of how the patient is moving and experiencing pain,” says Maura Iversen, BSc, PT, DPT, SD, MPH…

Filed under:Conditions Tagged with:Exercise/physical therapyphysical activityPhysical TherapyTechnology

Pain Management Research Sheds Light on Postsurgical Pain Sensitization, Opioid Risks, Nondrug Interventions

Susan Bernstein  |  March 20, 2017

WASHINGTON, D.C.—Successful management of pain remains a challenge for rheumatologists. Five research abstracts presented at the 2016 ACR/ARHP Annual Meeting in a session titled Pain—Basic and Clinical Aspects offered new insights on pain sensitization, and the risks and effects of various pain therapies. Knee Pain After Surgery Can we predict which patients will have longer-term…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)Managementnondrug interventionopioidPainpatient careQualityResearchrheumatologistrisk

Time to Rethink Inpatient Rehab After Knee Replacement?

Megan Brooks  |  March 14, 2017

NEW YORK (Reuters Health)—Inpatient rehabilitation did not lead to better mobility following total knee replacement compared with a home-based program in a randomized controlled trial (RCT) conducted in Australia. The findings do not support inpatient rehabilitation for adults undergoing uncomplicated total knee arthroplasty, conclude the authors in JAMA on March 14.1 “Normally, one study is…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:kneeknee arthroplastyrehabilitationtotal knee replacement

Weak Thigh Muscles Tied to Knee Osteoarthritis in Women

Lisa Rapaport  |  February 17, 2017

(Reuters Health)—Women with weaker thigh muscles may be more likely to develop knee osteoarthritis, a recent study suggests. Women with lower knee extensor strength were 47 percent more likely to develop knee arthritis than women who had stronger knee extensors, the study found. Weakness in the knee flexor muscles was associated with 41 percent greater…

Filed under:Osteoarthritis and Bone Disorders Tagged with:body mass index (BMI)knee extensor strengthknee flexor musclesknee osteoarthritisThigh Muscles

Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA

Kelly April Tyrrell  |  February 16, 2017

Guselkumab Improves Active Psoriatic Arthritis New research has revealed that patients with active psoriatic arthritis (PsA) and ≥3% body area of plaque psoriasis benefit from treatment with a human monoclonal antibody known as guselkumab (GUS). GUS is specific for the p19 subunit of interleukin 23 (IL-23). Patients in the Phase 2 clinical trial experienced significant…

Filed under:ConditionsDrug UpdatesPsoriatic ArthritisResearch Rheum Tagged with:Approvalsclinical trialsdrugFDAFX006guselkumabkneeMedicationOsteoarthritisoutcomepatient careplaque psoriasisPsoriatic ArthritisResearchrheumatologySafetyTreatment

FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Michele B. Kaufman, PharmD, BCGP  |  January 4, 2017

The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…

Filed under:AnalgesicsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:CancerFDAFood and Drug AdministrationFX006HIVkneeKnee Osteoarthritis (OA)Painpioglitazone

Low Levels of Vitamin D3 May Increase OA Pain

Lara C. Pullen, PhD  |  December 20, 2016

In a study of patients with knee osteoarthritis (OA), researchers found that the cytokine IL-17A may play a role in the pain associated with the disease. Specifically, decreased serum levels of vitamin D3 may contribute to OA pain via the regulation of immune responses…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:boneKnee Osteoarthritis (OA)osteoarthritis (OA)PainVitamin DVitamin D3

Brain Connectivity Predicts Placebo Response in Chronic Pain Patients

Will Boggs MD  |  November 2, 2016

NEW YORK (Reuters Health)—Brain connectivity differences predict placebo responses in patients with chronic knee osteoarthritis, researchers report. Positive medical responses to placebo treatments are common, but the underlying central nervous system mechanisms remain unclear. Dr. Marwan N. Baliki and colleagues from the Feinberg School of Medicine at Northwestern University in Chicago used resting-state functional MRI…

Filed under:Conditions Tagged with:brain connectivitychronic pain patientsgyrusknee osteoarthritisplacebo

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 59
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences